Streetbeat News

Stock Prices

MD

Analysts have varied opinions on Pediatrix Medical Group (NYSE:MD), with recent ratings showing a mix of bullish and indifferent sentiments. The average 12-month price target has increased by 21.37% to $10.62. Despite revenue growth, the company faces challenges with profitability and debt management.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 6:01 pm

VRDN

Analysts have varied ratings for Viridian Therapeutics (NASDAQ:VRDN), with a majority being bullish. Recent price targets have increased, indicating positive sentiment. Despite financial challenges, analysts maintain optimistic ratings, suggesting potential growth.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 6:00 pm

ENTA

Enanta Pharmaceuticals reported positive results from a Phase 2a study of its antiviral EDP-323 for RSV, showing significant reductions in viral load and symptoms. The drug, which has FDA Fast Track designation, demonstrated a favorable safety profile and pharmacokinetics. Enanta is also developing another RSV treatment, zelicapavir.

Portfolio Pulse from Vandana Singh

September 26, 2024 | 6:00 pm

ABT

Analysts have provided mixed ratings for Abbott Laboratories (NYSE:ABT) over the past three months, with a range of bullish to indifferent opinions. The average 12-month price target has increased by 2.95% to $126.83. Abbott's financial performance shows strong net margins and efficient asset management, despite lower revenue growth compared to peers.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 6:00 pm

NIO

Deep-pocketed investors are showing a bullish sentiment towards NIO, with significant options activity detected. The options market indicates a potential price range of $3.0 to $10.0 for NIO. Analysts have mixed ratings, with price targets ranging from $5 to $8.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 6:00 pm

KLAC

KLA (NASDAQ:KLAC) has significantly outperformed the market over the past 15 years, with an annualized return of 23.56%. A $100 investment in KLAC 15 years ago would now be worth $2,333.63, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 6:00 pm

FCNCA

First Citizens BancShares (NASDAQ:FCNCA) has significantly outperformed the market over the past 15 years, with an annualized return of 18.17%. A $1000 investment in FCNCA 15 years ago would now be worth $12,183.14, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 6:00 pm

VRDN

Viridian Therapeutics shares rose following BTIG's increase of its price target from $56 to $61.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 5:57 pm

MSFT

SONY

UBSFF

Ubisoft faces multiple challenges as Star Wars Outlaws underperforms, Assassin's Creed Shadows is delayed, and employee strikes loom. The company plans a strategic shift by releasing games on Steam to boost sales.

Portfolio Pulse from Franca Quarneti

September 26, 2024 | 5:53 pm

CMBM

Cambium Networks' shares rose following the announcement of a partnership with Beetel Teletech to distribute its network solutions in India.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 5:50 pm